Amelie M.
- Country
- France
- Department
- Oncologie médicale
Research Overview
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- TERTIO : Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a proof of concept randomized phase II study
- Evaluation of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma
Data & Insights
Has run more than one trial at 50 of 157 partner sites.
Specializations
Biliary Tract Cancer Research
Investigator specializes in developing therapeutic approaches for advanced biliary tract cancer, with particular emphasis on personalized medicine strategies and novel treatment combinations.
- Molecular-targeted therapies
- HER2-positive BTC treatment
- Second-line chemotherapy protocols
Research extends to evaluating targeted maintenance treatments and innovative therapeutic agents for biliary cancer management.
Hepatocellular Carcinoma Studies
Focus on investigating immunotherapy approaches for unresectable hepatocellular carcinoma, including combination treatments with innovative vaccine therapies.
- Immunotherapy combinations
- Anti-angiogenic treatments
- Novel vaccine strategies
Expertise in evaluating response rates to combined immunotherapeutic approaches in liver cancer treatment.
Pancreatic Cancer Treatment
Specialization in adjuvant therapy research for pancreatic ductal adenocarcinoma, focusing on post-resection treatment optimization.
- Adjuvant therapy protocols
- Combined treatment strategies
- Post-surgical interventions
Investigation of innovative therapeutic combinations to improve disease-free survival in resected pancreatic cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.